BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9895145)

  • 1. Co-administration of sertraline and haloperidol.
    Lee MS; Han CS; You YW; Kim SH
    Psychiatry Clin Neurosci; 1998 Dec; 52 Suppl():S193-8. PubMed ID: 9895145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia.
    Lee MS; Kim YK; Lee SK; Suh KY
    J Clin Psychopharmacol; 1998 Oct; 18(5):399-403. PubMed ID: 9790158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine.
    Potkin SG; Thyrum PT; Alva G; Bera R; Yeh C; Arvanitis LA
    J Clin Psychopharmacol; 2002 Apr; 22(2):121-30. PubMed ID: 11910256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma haloperidol and reduced haloperidol concentrations in a geriatric population.
    Chang WH; Jann MW; Chiang TS; Lin HN; Hu WH; Chien CP
    Neuropsychobiology; 1996; 33(1):12-6. PubMed ID: 8821369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients.
    Hesslinger B; Normann C; Langosch JM; Klose P; Berger M; Walden J
    J Clin Psychopharmacol; 1999 Aug; 19(4):310-5. PubMed ID: 10440457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia.
    Ulrich S; Neuhof S; Braun V; Meyer FP
    Int Clin Psychopharmacol; 1999 Jul; 14(4):219-28. PubMed ID: 10468314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Dose Reduction in Schizophrenia (DORIS) Study: a final report.
    Hirschowitz J; Hitzemann R; Piscani K; Burr G; Frecska E; Culliton D; Mann M; Curtis C
    Schizophr Res; 1997 Jan; 23(1):31-43. PubMed ID: 9050126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary retention with sertraline, haloperidol, and clonazepam combination.
    Benazzi F
    Can J Psychiatry; 1998 Dec; 43(10):1051-2. PubMed ID: 9868574
    [No Abstract]   [Full Text] [Related]  

  • 9. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables.
    Lane HY; Chang WH; Chang YC; Hu OY; Lin HN; Jann MW; Hu WH
    Psychiatry Res; 1997 Sep; 72(2):127-32. PubMed ID: 9335203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment.
    Ulrich S; Neuhof S; Braun V; Danos P; Pester U; Hoy L
    J Clin Psychopharmacol; 2000 Apr; 20(2):210-9. PubMed ID: 10770460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH; Lin SH; Jang FL
    J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose treatment with haloperidol: the effect of dose reduction.
    Volavka J; Cooper TB; Czobor P; Lindenmayer JP; Citrome LL; Mohr P; Bark N
    J Clin Psychopharmacol; 2000 Apr; 20(2):252-6. PubMed ID: 10770466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients.
    Jann MW; Crabtree BL; Pitts WM; Lam YW; Carter JG
    Neuropsychobiology; 1997; 36(1):32-6. PubMed ID: 9211442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open trial of adjunctive sertraline in the treatment of chronic schizophrenia.
    Thakore JH; Berti C; Dinan TG
    Acta Psychiatr Scand; 1996 Sep; 94(3):194-7. PubMed ID: 8891087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interindividual variation in bromperidol metabolism and relationship to therapeutic effects.
    Someya T; Muratake T; Hirokane G; Shibasaki M; Shimoda K; Takahashi S
    J Clin Psychopharmacol; 2000 Apr; 20(2):175-80. PubMed ID: 10770455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol.
    Sa AR; Hounie AG; Sampaio AS; Arrais J; Miguel EC; Elkis H
    Compr Psychiatry; 2009; 50(5):437-42. PubMed ID: 19683614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents.
    Glick ID; Lemmens P; Vester-Blokland E
    Int Clin Psychopharmacol; 2001 Sep; 16(5):265-74. PubMed ID: 11552769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia.
    Bisol LW; Brunstein MG; Ottoni GL; Ramos FL; Borba DL; Daltio CS; de Oliveira RV; Paz GE; de Souza SE; Bressan RA; Lara DR
    J Clin Psychiatry; 2008 Oct; 69(10):1572-9. PubMed ID: 19192440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
    Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
    J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.